Drug Detail:Erwinaze (Asparaginase erwinia chrysanthemi)
Generic Name: ASPARAGINASE ERWINIA CHRYSANTHEMI 10000[iU] in 1mL
Dosage Form: injection, powder, lyophilized, for solution
Drug Class: Miscellaneous antineoplastics
Drug Detail:Erwinaze (Asparaginase erwinia chrysanthemi)
Generic Name: ASPARAGINASE ERWINIA CHRYSANTHEMI 10000[iU] in 1mL
Dosage Form: injection, powder, lyophilized, for solution
Drug Class: Miscellaneous antineoplastics
To substitute for a dose of pegaspargase:
The recommended dose for each planned dose of pegaspargase is 25,000 International Units/m2 administered intramuscularly or intravenously three times a week (Monday/Wednesday/Friday) for six doses.
To substitute for a dose of native E. coli asparaginase:
The recommended dose is 25,000 International Units/m2 administered intramuscularly or intravenously for each scheduled dose of native E. coli asparaginase within a treatment.
When administering ERWINAZE intravenously, consider monitoring nadir (pre-dose) serum asparaginase activity (NSAA) levels and switching to intramuscular administration if desired NSAA levels are not achieved [see Clinical Pharmacology (12.3)].
Administer ERWINAZE in a setting with resuscitation equipment and other agents necessary to treat anaphylaxis.
ERWINAZE solution can be administered by intramuscular injection or by intravenous infusion.